Friday, December 10, 2021 1:03:25 PM
https://seekingalpha.com/instablog/2694641-biotechlab/5673583-dare-will-rocket-higher-partner-talks-percolate-fda-clears-dare-gel-for-bv-strong-buy
Summary
Partner talks percolate as FDA clears Daré gel for BV.
Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis.
"Strategic partnering discussions ongoing; Conference call will be scheduled once a definitive partnership agreement for commercialization of XACIATO in the U.S. is finalized and executed; U.S. commercial launch expected 2022."
Now is the time to buy DARE!
Daré Bioscience Inc.’s investors will have to wait a while for details regarding a commercialization partnership centered on Xaciato (2% clindamycin phosphate gel, formerly known as DARE-BV1) as a single-dose treatment of bacterial vaginosis in females 12 years of age and older. Approved Dec. 7, Xaciato is expected to launch next year.
https://www.bioworld.com/articles/514071-partner-talks-percolate-as-fda-clears-daré-gel-for-bv?v=preview
The dumbest people I know are those who know it all.
Malcolm Forbes
Recent DARE News
- Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% • GlobeNewswire Inc. • 08/26/2024 12:00:00 PM
- Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% • GlobeNewswire Inc. • 08/13/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:05:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:01:31 PM
- Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update • GlobeNewswire Inc. • 08/12/2024 08:01:00 PM
- Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024 • GlobeNewswire Inc. • 08/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 12:05:26 PM
- Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule • GlobeNewswire Inc. • 07/19/2024 12:00:00 PM
- Daré Bioscience Announces Reverse Stock Split • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder • GlobeNewswire Inc. • 06/24/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:15:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:15:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:15:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:05:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:01:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 12:05:24 PM
- Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/13/2024 04:15:35 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/10/2024 08:12:44 PM
- Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024 • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update • GlobeNewswire Inc. • 03/28/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM